Adjuvant chemotherapy options for early stage non-small cell lung cancer

For many years adjuvant chemotherapy has been a standard treatment after complete resection in malignancies such as breast and colon but only recently has its use become standard in early stage non-small cell lung cancer (NSCLC). Although surgery is regarded as the best possible treatment for early...

Full description

Bibliographic Details
Main Authors: Manali ePatel, Heather A Wakelee
Format: Article
Language:English
Published: Frontiers Media S.A. 2011-11-01
Series:Frontiers in Oncology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00045/full
_version_ 1818509801011806208
author Manali ePatel
Heather A Wakelee
author_facet Manali ePatel
Heather A Wakelee
author_sort Manali ePatel
collection DOAJ
description For many years adjuvant chemotherapy has been a standard treatment after complete resection in malignancies such as breast and colon but only recently has its use become standard in early stage non-small cell lung cancer (NSCLC). Although surgery is regarded as the best possible treatment for early stage NSCLC, only 20-25% of patients have resectable disease at presentation. Despite optimal surgical treatment, five-year survival rates for NSCLC remain 50-60% for stage IB, 40%-50% for stage II, and 20-30% for stage III (Kohler 2011; Siegel 2011). Adjuvant chemotherapy provides additional survival benefit in resected NSCLC but questions remain as to how to select patients for therapy and which regimen is best. Other than work with tegafur/uracil in Japan, the positive adjuvant trials have all utilized a cisplatin backbone, but the drug(s) to pair with cisplatin are a matter of debate and will be discussed further in this manuscript.
first_indexed 2024-12-10T22:50:25Z
format Article
id doaj.art-53fd0ff67fed42b09b1bf1357b3a1160
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-10T22:50:25Z
publishDate 2011-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-53fd0ff67fed42b09b1bf1357b3a11602022-12-22T01:30:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2011-11-01110.3389/fonc.2011.0004515959Adjuvant chemotherapy options for early stage non-small cell lung cancerManali ePatel0Heather A Wakelee1Stanford UniversityStanford UniversityFor many years adjuvant chemotherapy has been a standard treatment after complete resection in malignancies such as breast and colon but only recently has its use become standard in early stage non-small cell lung cancer (NSCLC). Although surgery is regarded as the best possible treatment for early stage NSCLC, only 20-25% of patients have resectable disease at presentation. Despite optimal surgical treatment, five-year survival rates for NSCLC remain 50-60% for stage IB, 40%-50% for stage II, and 20-30% for stage III (Kohler 2011; Siegel 2011). Adjuvant chemotherapy provides additional survival benefit in resected NSCLC but questions remain as to how to select patients for therapy and which regimen is best. Other than work with tegafur/uracil in Japan, the positive adjuvant trials have all utilized a cisplatin backbone, but the drug(s) to pair with cisplatin are a matter of debate and will be discussed further in this manuscript.http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00045/fullchemotherapylung cancerTreatmentadjuvantoptionsselection
spellingShingle Manali ePatel
Heather A Wakelee
Adjuvant chemotherapy options for early stage non-small cell lung cancer
Frontiers in Oncology
chemotherapy
lung cancer
Treatment
adjuvant
options
selection
title Adjuvant chemotherapy options for early stage non-small cell lung cancer
title_full Adjuvant chemotherapy options for early stage non-small cell lung cancer
title_fullStr Adjuvant chemotherapy options for early stage non-small cell lung cancer
title_full_unstemmed Adjuvant chemotherapy options for early stage non-small cell lung cancer
title_short Adjuvant chemotherapy options for early stage non-small cell lung cancer
title_sort adjuvant chemotherapy options for early stage non small cell lung cancer
topic chemotherapy
lung cancer
Treatment
adjuvant
options
selection
url http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00045/full
work_keys_str_mv AT manaliepatel adjuvantchemotherapyoptionsforearlystagenonsmallcelllungcancer
AT heatherawakelee adjuvantchemotherapyoptionsforearlystagenonsmallcelllungcancer